Tumor-Associated Trypsin Inhibitor (TATI) as a Biomarker of Poor Prognosis in Oropharyngeal Squamous Cell Carcinoma Irrespective of HPV Status
Simple Summary
- Supplementary File 1:
ZIP-Document (ZIP, 149 KiB)
Sjöblom, A.; Stenman, U.-H.; Hagström, J.; Jouhi, L.; Haglund, C.; Syrjänen, S.; Mattila, P.; Mäkitie, A.; Carpén, T. Tumor-Associated Trypsin Inhibitor (TATI) as a Biomarker of Poor Prognosis in Oropharyngeal Squamous Cell Carcinoma Irrespective of HPV Status. Cancers 2021, 13, 2811. https://doi.org/10.3390/cancers13112811
Sjöblom A, Stenman U-H, Hagström J, Jouhi L, Haglund C, Syrjänen S, Mattila P, Mäkitie A, Carpén T. Tumor-Associated Trypsin Inhibitor (TATI) as a Biomarker of Poor Prognosis in Oropharyngeal Squamous Cell Carcinoma Irrespective of HPV Status. Cancers. 2021; 13(11):2811. https://doi.org/10.3390/cancers13112811
Chicago/Turabian StyleSjöblom, Anni, Ulf-Håkan Stenman, Jaana Hagström, Lauri Jouhi, Caj Haglund, Stina Syrjänen, Petri Mattila, Antti Mäkitie, and Timo Carpén. 2021. "Tumor-Associated Trypsin Inhibitor (TATI) as a Biomarker of Poor Prognosis in Oropharyngeal Squamous Cell Carcinoma Irrespective of HPV Status" Cancers 13, no. 11: 2811. https://doi.org/10.3390/cancers13112811